S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

TSE:TRLTrilogy International Partners Stock Price, Forecast & News

C$1.17
+0.01 (+0.86 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
C$1.10
Now: C$1.17
C$1.17
50-Day Range
C$1.04
MA: C$1.23
C$1.45
52-Week Range
C$0.83
Now: C$1.17
C$3.45
Volume1,100 shs
Average Volume29,612 shs
Market CapitalizationC$68.89 million
P/E RatioN/A
Dividend Yield1.43%
BetaN/A
Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communication services in Bolivia and New Zealand. The company's communications services include local, international long distance, and roaming services for customers and international visitors roaming on their networks. It also provides fixed broadband communications services to business and residential customers. The company serves 15.9 million customers. Trilogy International Partners Inc. is headquartered in Bellevue, Washington.
Read More
Trilogy International Partners logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-425-4585900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$658.96 million
Cash FlowC$0.83 per share
Book ValueC($1.10) per share

Profitability

Miscellaneous

Employees1,821
Market CapC$68.89 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive TRL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRL and its competitors with MarketBeat's FREE daily newsletter.

Trilogy International Partners (TSE:TRL) Frequently Asked Questions

How has Trilogy International Partners' stock been impacted by COVID-19 (Coronavirus)?

Trilogy International Partners' stock was trading at C$1.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TRL stock has decreased by 38.4% and is now trading at C$1.17. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Trilogy International Partners?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trilogy International Partners.

When is Trilogy International Partners' next earnings date?

Trilogy International Partners is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Trilogy International Partners.

What price target have analysts set for TRL?

2 equities research analysts have issued 12-month price targets for Trilogy International Partners' stock. Their forecasts range from C$1.70 to C$3.30. On average, they anticipate Trilogy International Partners' share price to reach C$2.50 in the next year. This suggests a possible upside of 113.7% from the stock's current price. View analysts' price targets for Trilogy International Partners.

Has Trilogy International Partners been receiving favorable news coverage?

News coverage about TRL stock has been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trilogy International Partners earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Trilogy International Partners.

Who are some of Trilogy International Partners' key competitors?

What other stocks do shareholders of Trilogy International Partners own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Emera (EMA), Millicom International Cellular (MIICF), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONCYF), CSX (CSX), Check Cap (CHEK), Citizens Financial Group (CFG), Cboe Global Markets (CBOE) and CAE (CAE).

Who are Trilogy International Partners' key executives?

Trilogy International Partners' management team includes the following people:
  • Mr. John William Stanton, Chairman (Age 64)
  • Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
  • Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
  • Mr. Erik Mickels, Sr. VP & CFO
  • Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.

What is Trilogy International Partners' stock symbol?

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

How do I buy shares of Trilogy International Partners?

Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Trilogy International Partners' stock price today?

One share of TRL stock can currently be purchased for approximately C$1.17.

How big of a company is Trilogy International Partners?

Trilogy International Partners has a market capitalization of C$68.89 million and generates C$658.96 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe.

What is Trilogy International Partners' official website?

The official website for Trilogy International Partners is www.trilogy-international.co....

How can I contact Trilogy International Partners?

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.